Cure My Disease

Don't miss your cure!

 Log in / Sign up

Thyroid cancer trial tests faster hormone control after radioiodine

NCT ID NCT06647602

Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 40 people with high-risk differentiated thyroid cancer who need radioactive iodine therapy. After stopping their own thyroid hormones, participants will receive either standard levothyroxine alone or levothyroxine plus liothyronine. The goal is to see which approach brings thyroid-stimulating hormone (TSH) to the target level more quickly, which may help manage the disease better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
levothyroxine and liothyronine (thyroid hormone replacement drugs)
What this could lead to
If successful, this could show that adding liothyronine to standard levothyroxine helps thyroid cancer patients reach target hormone levels more quickly after radioiodine treatment.
What could go wrong
This is a small, early-stage study (40 participants) that only measures short-term hormone levels, not long-term cancer outcomes. The results may not apply to all thyroid cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include patients with a histologically confirmed high-risk DTC, men and women aged 18-75 years. Patients have to be prepared to RAI with TH-withdrawal and treated according to the ATA guidelines.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma) * Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician). * Prepared for RAI-therapy with TH-withdrawal * Patients must be fit to adhere to the study protocol * Patients must be able to read and understand the Dutch language Exclusion Criteria: * Pregnancy * Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable. * Conditions or drugs interfering with thyroid hormone uptake: * Patients with a history of atrophic gastritis * Patients using proton-pomp inhibitors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differentiated thyroid cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Differentiated thyroid cancer Levothyroxine Liothyronine Thyroid cancer Thyroid hormones

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Radboud University Nijmegen

    Nijmegen, Netherlands

  • University Medical Center Groningen (UMCG)

    Groningen, Provincie Groningen, 9700RB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.